Weekly Bortezomib Administration in VRd for 4-Week Cycles
For VRd with weekly bortezomib administered over 4-week cycles, use the "VRd-lite" schedule: bortezomib 1.3 mg/m² subcutaneously on days 1,8,15, and 22; lenalidomide 25 mg orally on days 1-21; dexamethasone 20 mg on the day of and day after each bortezomib dose; repeat every 28 days until progression. 1
Standard VRd-Lite Dosing Schedule
The modified 4-week VRd-lite regimen provides an optimal balance between efficacy and tolerability for patients requiring weekly bortezomib dosing:
- Bortezomib: 1.3 mg/m² subcutaneously on days 1,8,15, and 22 of each 28-day cycle 1
- Lenalidomide: 25 mg orally on days 1-21 of each 28-day cycle 1
- Dexamethasone: 20 mg on the day of and day after each bortezomib administration 1
- Alternative: 40 mg on days 1,8,15, and 22 2
Route of Administration
Subcutaneous bortezomib is strongly preferred over intravenous administration. 1 This route provides equivalent anti-myeloma efficacy while markedly reducing peripheral neuropathy risk—a critical consideration for continuous therapy until progression. 1
Duration and Continuation
Continue VRd-lite therapy until disease progression or unacceptable toxicity. 1 This continuous approach is superior to fixed-duration therapy:
- For transplant-eligible patients: typically 3-4 cycles before stem cell collection 1
- For transplant-ineligible patients: maintain until progression with dose modifications as needed 1
- Continuous therapy yields superior progression-free and overall survival compared to fixed-duration approaches 3, 1
Clinical Efficacy Evidence
The weekly bortezomib schedule in 4-week cycles demonstrates robust outcomes:
- Overall response rate: 86% with very good partial response or better in 66% of patients 4
- Median progression-free survival: 35.1 months 4
- Median overall survival: Not reached at 30 months median follow-up 4
- Real-world data from 2,497 patients showed no significant difference in PFS (37.2 vs 39.6 months, p=0.906) or OS between weekly and twice-weekly bortezomib schedules 5
Safety Profile and Neuropathy Risk
Weekly bortezomib markedly reduces peripheral neuropathy compared to twice-weekly dosing:
- Peripheral neuropathy incidence: 18.5% with weekly vs 34.7% with twice-weekly (p<0.001) 5
- Grade ≥2 peripheral neuropathy: 0% with modified VRd-lite vs 27.2% with twice-weekly VRd (p=0.003) 6
- Only 2% of patients experienced grade 3 peripheral neuropathy symptoms with VRd-lite 4
Important Clinical Considerations
Dose adjustments for renal dysfunction: Lenalidomide requires dose reduction based on creatinine clearance in patients with renal impairment; these reductions do not compromise efficacy. 3, 1 Bortezomib does not require dose adjustment for renal dysfunction. 3
Herpes zoster prophylaxis is mandatory for all patients receiving proteasome inhibitors. 7
Avoid intravenous bortezomib when subcutaneous formulation is available, as IV administration increases neuropathy risk without added benefit. 1
Comparison to Standard 3-Week VRd
The traditional 3-week VRd schedule uses bortezomib on days 1,8, and 15 only, with lenalidomide on days 1-14 of 21-day cycles. 2, 1 The 4-week VRd-lite schedule adds a fourth weekly bortezomib dose (day 22) and extends lenalidomide to days 1-21, providing more sustained drug exposure with improved tolerability. 1
Quadruplet Regimens Exception
When combining VRd with daratumumab or isatuximab, the bortezomib schedule changes to twice-weekly dosing (days 1,4,8,11) during cycles 1-8. 7, 1 This intensive schedule is associated with higher peripheral neuropathy rates (approximately 27% grade ≥2) but achieves deeper responses with higher MRD-negativity rates. 7 After cycle 8, therapy typically transitions to weekly dosing or discontinues bortezomib in favor of lenalidomide/dexamethasone maintenance. 7